Grifols company profile
Company profile
Grifols has 25,000 employees and is headquartered in Barcelona, Spain.
Based in Barcelona, Grifols has been in operation since 1909. The company researches, develops, produces and markets plasma-derived medicines, including albumin, immunoglobulins and thrombin sold to pharma and biotech companies, along with diagnostic testing equipment and reagents, transfusion medicine and clinical diagnostics. Its hospital offering covers intravenous solutions, clinical nutrition, hospital automation systems and medical devices for areas such as interventional neuroradiology, hemodynamics and cardiovascular surgery. Operations span the United States, Canada, Spain, Europe and other markets, organised into the Biopharma, Diagnostic, Bio Supplies and Other segments.
In the fiscal year ended December 2025, Grifols reported revenue of EUR 7.5 billion, up 4.3% from the previous year, and net profit of EUR 402 million. The company employs 25,000 people and has its headquarters in Barcelona, Spain.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- Spain
- Headquarters
- Parque Empresarial Can Sant Joan, 08174, Barcelona
- Employees
- 25,000
- Chief executive
- Jose Ignacio Abia Buenache
- Founded
- 1909
- Fiscal year
- January - December
- Listing
- GRF · BME
- Indices
- IBEX 35
- Currency
- EUR
- ISIN
- ES0171996087
- Website
- grifols.com
Grifols and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| GrifolsGRF | Spain | $8.76B | 25,000 | 18.9% | 16.4 |
| RecordatiREC | Italy | $12.11B | 4,700 | 32.6% | 21.0 |
| OrionORNAV | Finland | $15.93B | 4,215 | 38.1% | 22.0 |
| VirbacVIRP | France | $3.28B | 6,442 | 15.8% | 19.1 |
| BayerBAYN | Germany | $61.37B | 87,775 | 16.5% | — |
| GSKGSK | United Kingdom | $101.36B | 66,841 | 30.5% | 17.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
